Entrada Therapeutics is a biotechnology business based in the US. Entrada Therapeutics shares (TRDA) are listed on the NASDAQ and all prices are listed in US Dollars. Entrada Therapeutics employs 160 staff and has a trailing 12-month revenue of around $162.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $17.10 |
|---|---|
| 52-week range | $10.75 - $18.17 |
| 50-day moving average | $15.37 |
| 200-day moving average | $14.50 |
| Wall St. target price | $21.50 |
| PE ratio | 24.6087 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.69 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $17.1 from 2024-07-25
| 1 week (2024-07-19) | 0.71% |
|---|---|
| 1 month (2024-06-27) | 20.68% |
| 3 months (2024-04-26) | 37.35% |
| 6 months (2024-01-26) | 15.31% |
| 1 year (2023-07-27) | 2.27% |
|---|---|
| 2 years (2022-07-27) | 41.21% |
| 3 years (2021-07-23) | N/A |
| 5 years (2019-07-23) | N/A |
Valuing Entrada Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Entrada Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Entrada Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Entrada Therapeutics shares trade at around 25x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Entrada Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Entrada Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $27 million.
The EBITDA is a measure of a Entrada Therapeutics's overall financial performance and is widely used to measure a its profitability.
To put Entrada Therapeutics's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $162.9 million |
|---|---|
| Operating margin TTM | 35.71% |
| Gross profit TTM | $0 |
| Return on assets TTM | 3.01% |
| Return on equity TTM | 9.41% |
| Profit margin | 14.42% |
| Book value | $8.53 |
| Market Capitalization | $573.2 million |
TTM: trailing 12 months
We're not expecting Entrada Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Entrada Therapeutics's shares have ranged in value from as little as $10.75 up to $18.17. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Entrada Therapeutics's is -0.257. This would suggest that Entrada Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Entrada Therapeutics has bucked the trend.
To put Entrada Therapeutics's beta into context you can compare it against those of similar companies.
Entrada Therapeutics, Inc. , a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701.
Learn how to invest in Cathie Wood’s ARK Venture Fund in 5 easy steps.
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Learn these options trading strategies to lock in profits and get acquainted with a new asset class.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.